Whitten C W, Allison P M, Morse L M, Latson T W
Department of Anesthesiology and Pain Management, University of Texas Southwestern Medical Center at Dallas 75235-9068.
J Clin Anesth. 1994 Nov-Dec;6(6):515-20. doi: 10.1016/0952-8180(94)90096-5.
The perioperative management of two patients undergoing complex "redo" cardiac surgical procedures are presented. The management of both patients included the prophylactic administration of aprotinin via a "compassionate use" protocol. Aprotinin, a serine protease inhibitor, has been shown to limit the exposure to blood and blood products in patients undergoing high-risk cardiac surgical procedures. In late December 1993, the Food and Drug Administration approved aprotinin for administration to cardiac surgical patients considered at high risk for post-cardiopulmonary bypass coagulopathies. Indications for the administration of aprotinin, as well as a brief review of the literature relating to the perioperative administration of aprotinin, are included.
本文介绍了两名接受复杂“再次”心脏外科手术患者的围手术期管理。两名患者的管理均包括通过“同情用药”方案预防性给予抑肽酶。抑肽酶是一种丝氨酸蛋白酶抑制剂，已被证明可减少高危心脏外科手术患者对血液和血制品的接触。1993年12月下旬，美国食品药品监督管理局批准将抑肽酶用于被认为有体外循环后凝血病高危风险的心脏外科手术患者。文中还包括了抑肽酶的给药指征以及与抑肽酶围手术期给药相关的文献简要综述。
